FinancingsClovis Oncology Inc. set terms for its proposed $130.2 million initial public offering.Dynavax Technologies Corp. raised $60 million in a public stock offering.Human Genome Sciences Inc. priced a public offering of $494.5 million in convertible senior notes.Karyopharm Therapeutics Inc. completed a $10 million Series A2 financing.Verastem Inc. filed to raise $50 million in an initial public offering.Deals